CA2934094C - Benzimidazole derivatives as ep4-ligands - Google Patents

Benzimidazole derivatives as ep4-ligands Download PDF

Info

Publication number
CA2934094C
CA2934094C CA2934094A CA2934094A CA2934094C CA 2934094 C CA2934094 C CA 2934094C CA 2934094 A CA2934094 A CA 2934094A CA 2934094 A CA2934094 A CA 2934094A CA 2934094 C CA2934094 C CA 2934094C
Authority
CA
Canada
Prior art keywords
alkyl
methyl
radicals
cycloalkyl
polysubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2934094A
Other languages
English (en)
French (fr)
Other versions
CA2934094A1 (en
Inventor
Olaf Peters
Nico Brauer
Ulrich Bothe
Marcus Koppitz
Jens Nagel
Gernot Langer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Animal Health GmbH
Original Assignee
Bayer Animal Health GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Animal Health GmbH filed Critical Bayer Animal Health GmbH
Publication of CA2934094A1 publication Critical patent/CA2934094A1/en
Application granted granted Critical
Publication of CA2934094C publication Critical patent/CA2934094C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2934094A 2013-12-19 2014-12-16 Benzimidazole derivatives as ep4-ligands Active CA2934094C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13198448.6 2013-12-19
EP13198448 2013-12-19
PCT/EP2014/077955 WO2015091475A1 (de) 2013-12-19 2014-12-16 Benzimidazolderivate als ep4-liganden

Publications (2)

Publication Number Publication Date
CA2934094A1 CA2934094A1 (en) 2015-06-25
CA2934094C true CA2934094C (en) 2022-07-26

Family

ID=49876417

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2934094A Active CA2934094C (en) 2013-12-19 2014-12-16 Benzimidazole derivatives as ep4-ligands

Country Status (11)

Country Link
US (1) US10730856B2 (zh)
EP (1) EP3083603B1 (zh)
JP (1) JP6411513B2 (zh)
CN (1) CN105814038B (zh)
AR (1) AR098843A1 (zh)
CA (1) CA2934094C (zh)
ES (1) ES2651857T3 (zh)
HK (1) HK1223355A1 (zh)
TW (1) TW201607943A (zh)
UY (1) UY35906A (zh)
WO (1) WO2015091475A1 (zh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA115576C2 (uk) * 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
TW201607943A (zh) 2013-12-19 2016-03-01 拜耳製藥公司 作為ｅｐ４配體之新穎苯并咪唑衍生物
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
WO2018162562A1 (en) * 2017-03-10 2018-09-13 Bayer Pharma Aktiengesellschaft Use of an ep4 antagonist for the treatment of inflammatory pain
ES2893452T3 (es) 2017-05-18 2022-02-09 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de PGE2
TW201900180A (zh) 2017-05-18 2019-01-01 瑞士商愛杜西亞製藥有限公司 嘧啶衍生物
CA3063632A1 (en) 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd Benzofurane and benzothiophene derivatives as pge2 receptor modulators
MA49128A (fr) 2017-05-18 2021-03-17 Idorsia Pharmaceuticals Ltd Dérivés de pyrimidine utilisés en tant que modulateurs des récepteurs des pge2
PE20191787A1 (es) 2017-05-18 2019-12-24 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituidos
KR20230107228A (ko) 2020-11-13 2023-07-14 오노 야꾸힝 고교 가부시키가이샤 Ep4 길항약과 면역 체크포인트 저해 물질의 병용에 의한 암 치료
CN114249660B (zh) * 2021-12-10 2024-04-09 浙江工业大学 一种利用含醚键醇类衍生物的n-烷基化反应制备含醚芳胺衍生物的方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001007409A1 (en) * 1999-07-23 2001-02-01 Astrazeneca Uk Limited Carbazole derivatives and their use as neuropeptide y5 receptor ligands
CN101934078A (zh) 2000-01-18 2011-01-05 拜耳先灵医药股份有限公司 包含屈螺酮和雌激素的药物组合物及其应用
HN2001000224A (es) 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
KR100592007B1 (ko) 2002-04-12 2006-06-21 화이자 인코포레이티드 Ｉｌ-６ 관련 질환 치료에서의 ｅｐ４ 수용체 리간드의용도
MXPA05000812A (es) * 2002-07-31 2005-04-19 Euro Celtique Sa Bencimidazoles aril sustituidos y su uso como bloqueadores del canal de sodio.
US6949564B2 (en) 2002-12-18 2005-09-27 Pfizer Inc. NPY-5 antagonists
KR101094003B1 (ko) 2003-01-29 2011-12-15 아스터랜드 유케이 리미티드 Ｅｐ4 수용체 길항제
ES2441206T3 (es) 2003-09-03 2014-02-03 Raqualia Pharma Inc. Compuestos de fenil o piridilamida como antagonistas de la prostaglandina E2
BRPI0509993A (pt) * 2004-04-20 2007-10-16 Pfizer Prod Inc combinações compreendendo ligandos de alfa-2-delta
CA2565660C (en) 2004-05-04 2009-11-03 Pfizer Inc. Ortho substituted aryl or heteroaryl amide compounds
JP5244091B2 (ja) 2006-04-24 2013-07-24 メルク カナダ インコーポレイテッド Ｅｐ４受容体アンタゴニストとしてのインドールアミド誘導体
GB0614066D0 (en) * 2006-07-14 2006-08-23 Glaxo Group Ltd Compounds
US8969394B2 (en) 2006-08-11 2015-03-03 Merck Frosst Canada Ltd. Thiophenecarboxamide derivatives as EP4 receptor ligands
CA2679175C (en) 2007-02-26 2015-01-13 Merck Frosst Canada Ltd. Indole and indoline cyclopropyl amide derivatives as ep4 receptor antagonists
DE102007011105A1 (de) 2007-03-02 2008-09-04 Bayer Schering Pharma Aktiengesellschaft Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose
EP2172447A4 (en) 2007-07-03 2011-08-24 Astellas Pharma Inc amide
CN102026991A (zh) 2007-08-09 2011-04-20 默沙东公司 制造噻吩甲酰胺衍生物的方法
TW201029986A (en) * 2008-11-14 2010-08-16 Neurosearch As Novel compounds
WO2010124097A2 (en) 2009-04-22 2010-10-28 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
JP6152643B2 (ja) 2010-02-22 2017-06-28 株式会社ＡｓｋＡｔ Ｉｌ−２３媒介疾患を治療するためのｅｐ４受容体拮抗薬の使用
UA115576C2 (uk) * 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
TW201607943A (zh) 2013-12-19 2016-03-01 拜耳製藥公司 作為ｅｐ４配體之新穎苯并咪唑衍生物

Also Published As

Publication number Publication date
JP2017500327A (ja) 2017-01-05
HK1223355A1 (zh) 2017-07-28
US20160318905A1 (en) 2016-11-03
TW201607943A (zh) 2016-03-01
UY35906A (es) 2015-07-31
EP3083603A1 (de) 2016-10-26
JP6411513B2 (ja) 2018-10-24
US10730856B2 (en) 2020-08-04
EP3083603B1 (de) 2017-09-13
CN105814038A (zh) 2016-07-27
CN105814038B (zh) 2018-12-04
CA2934094A1 (en) 2015-06-25
ES2651857T3 (es) 2018-01-30
WO2015091475A1 (de) 2015-06-25
AR098843A1 (es) 2016-06-15

Similar Documents

Publication Publication Date Title
CA2934094C (en) Benzimidazole derivatives as ep4-ligands
CA2893630C (en) Novel benzimidazole derivatives as ep4 antagonists
TW200533641A (en) Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as orl1-receptor antagonists
WO2010118921A1 (en) Novel p2x7r antagonists and their use
CN101568547A (zh) 作为17βHSD抑制剂的被取代的雌三烯衍生物
JP2012502975A (ja) 治療において有用なアミド化合物
TW200819434A (en) 1-(het)aryl-3-[hetaryl-piperidin-4-yl]-thioureas as modulators of the EP2 receptor
WO2010012396A1 (de) 5,6 substituierte benzamid-derivate als modulatoren des ep2-rezeptors
EP0650480B1 (en) 1-arylsulphonyl-3-phenyl-1,4,5,6-tetrahydropyridazines
WO2013152683A1 (zh) 双环取代吡唑酮偶氮类衍生物、其制备方法及用途
WO2010101128A1 (ja) アミド化合物
WO2010012399A1 (de) Indolytamide als modulatoren des ep2-rezeptors
AU2021355480A1 (en) Imidazopiperazine inhibitors of transcription activating proteins
US20100029599A1 (en) Indolylamides as modulators of the EP2 receptor

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20191213

EEER Examination request

Effective date: 20191213

EEER Examination request

Effective date: 20191213